Align Technology, Inc. $ALGN Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 0.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 501,763 shares of the medical equipment provider’s stock after buying an additional 3,392 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.69% of Align Technology worth $94,999,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ALGN. Vanguard Group Inc. grew its stake in shares of Align Technology by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock valued at $1,341,031,000 after buying an additional 185,187 shares during the period. Invesco Ltd. boosted its holdings in Align Technology by 12.7% in the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock valued at $193,764,000 after acquiring an additional 137,553 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Align Technology by 32.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock valued at $132,221,000 after acquiring an additional 202,616 shares during the period. Navera Investment Management Ltd. increased its stake in Align Technology by 3.0% during the second quarter. Navera Investment Management Ltd. now owns 787,559 shares of the medical equipment provider’s stock worth $149,126,000 after acquiring an additional 23,080 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Align Technology by 0.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 736,635 shares of the medical equipment provider’s stock worth $117,022,000 after acquiring an additional 4,789 shares during the last quarter. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALGN has been the subject of a number of research reports. Stifel Nicolaus set a $200.00 target price on Align Technology in a report on Thursday, October 30th. HSBC boosted their price objective on shares of Align Technology from $140.00 to $150.00 in a research note on Friday, October 31st. Jefferies Financial Group raised their target price on shares of Align Technology from $140.00 to $155.00 in a research note on Thursday, October 30th. UBS Group reduced their target price on shares of Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. Finally, Weiss Ratings downgraded Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $175.45.

Align Technology Price Performance

Align Technology stock opened at $147.14 on Friday. Align Technology, Inc. has a 12-month low of $122.00 and a 12-month high of $246.19. The company has a market capitalization of $10.56 billion, a price-to-earnings ratio of 28.51, a price-to-earnings-growth ratio of 1.49 and a beta of 1.84. The firm’s fifty day moving average price is $134.45 and its 200 day moving average price is $156.66.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.23. Align Technology had a return on equity of 14.06% and a net margin of 9.50%.The company had revenue of $995.69 million during the quarter, compared to the consensus estimate of $980.75 million. During the same period last year, the firm earned $2.35 earnings per share. The company’s revenue was up 1.8% on a year-over-year basis. Align Technology has set its Q4 2025 guidance at EPS. Analysts forecast that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology declared that its Board of Directors has initiated a share buyback plan on Tuesday, August 5th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.